Vaginitis is a frequently occurring medical disorder in women associated with substantial morbidity and formerly undetected complications. Extensive research in the past few years has led to the development of diagnostic tools as well as treatment modalities for all forms of vaginitis. Vaginitis is an infection of the vagina that can result in itching, discharge, and pain. Candida or "yeast" infections, bacterial vaginosis, tyrichomoniasis vaginitis, chlamydia vaginitis, and viral vaginitis are the major forms of vaginitis. Around one third women across the globe experience indications of vaginitis at some point in their lifetime. Women are highly susceptible to vaginitis during the reproductive age; a change in balance of bacteria and yeast present in vagina can result in vaginitis.
The global vaginitis therapeutics market is expected to grow during the forecast years due to increasing number of women of reproductive age across the globe and changes in dietary patterns. The vaginitis therapeutics market is also driven by various government initiatives for public health programs for women such as increase in the overall health care spending. The market is likely to be negatively affected by high cost of research and development involved and drug development challenges in emerging economies. Increasing resistance to conventional antibiotics is projected to be the key driver of the vaginitis therapeutics market during the forecast period. Increasing use of antibiotics to treat various infections and diseases and women health disorders is likely to fuel the growth of the vaginitis therapeutics market during the forecast period.
The vaginitis therapeutics market has been segmented based on medication, end-user, and region. In terms of medication, the market has been segmented into antifungal agents, antibiotics, and hormones. Antifungal agents are classified into miconazole, clotrimazole, terconazole, tioconazole, butoconazole, fluconazole, and ketoconazole. Miconazole is an antifungal medication used to treat ring worm and yeast infections of vagina. Clotrimazole is an antifungal agent used to treat vaginal yeast infections. Tioconazole imidazole class is used to treat infections caused by a fungus or yeast. Antibiotics are further classified into clindamycin, ceftriaxone, erythromycin, metronidazole, cefixime, doxycycline, and azythromycin. Clindamycin and ceftriaxone are antibiotics used to treat bacterial vaginosis. Hormonal medications include estrogen, as some skin disorders and reduced estrogen levels after menopause can cause vaginitis infection. Based on end-user, the vaginitis therapeutics market has been segmented into hospitals, ambulatory surgical centers, specialized gynecology centers, and clinics.
In terms of region, the vaginitis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the market for vaginitis therapeutics owing to rising awareness among people, early treatment adoption, and new product innovations. Europe is the second leading market for vaginitis therapeutics due to development of new drugs and expansion of more efficient and advanced technologies. The vaginitis therapeutics market in Asia Pacific is also anticipated to witness rapid growth owing to increasing health care spending, adoption of western lifestyle, and rise in research and development. Asia Pacific is the fastest growing market for vaginitis therapeutics as several players have invested in the development of new drugs. These factors are expected to drive the global vaginitis therapeutics market during the forecast period.
Major players in the vaginitis therapeutics market are Pfizer, Inc., Janssen Pharmaceuticals, Abbott Laboratories, GlaxoSmithKline plc, Sanofi, Novartis AG, Bayer AG, Bristol-Myers-Squibb Company, Eli Lilly and Company, Merck & Co. Inc., Astellas Pharma, Inc., Enzon Pharmaceuticals, Inc., Galderma SA, Gilead Sciences, Inc., Medicis Pharmaceutical Corp., Teva Pharmaceutical Industries, Ltd., and Starpharma Holdings Limited. Rising demand for alternatives for conventional antibiotics is likely to increase competition between market players in the vaginitis therapeutics market.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.